Den europeiske union - norsk - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - andre dermatologiske preparater - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Norge - norsk - Statens legemiddelverk

2care4 aps - fusidinsyrehemihydrat / betametasonvalerat - gel - 5 mg/ g / 1 mg/ g